Eli Lilly And Stock Today

LLY Stock  USD 795.35  7.16  0.91%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Less than 3

 
High
 
Low
Very Low
Eli Lilly is trading at 795.35 as of the 30th of November 2024; that is 0.91% up since the beginning of the trading day. The stock's open price was 788.19. Eli Lilly has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Note, on November 7, 2024, Senator Sheldon Whitehouse of US Senate acquired $15k to $50k worth of Eli Lilly's common stock.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
13th of January 1978
Category
Healthcare
Classification
Health Care
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. Eli Lilly operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. The company has 899.32 M outstanding shares of which 6.54 M shares are now shorted by investors with about 1.54 days to cover. More on Eli Lilly and

Moving together with Eli Stock

  0.76HLN Haleon plcPairCorr
  0.86JNJ Johnson Johnson Sell-off TrendPairCorr
  0.9PFE Pfizer Inc Aggressive PushPairCorr
  0.81ANRO Alto Neuroscience,PairCorr
  0.77SHG Shinhan FinancialPairCorr

Moving against Eli Stock

  0.8FNMFO Federal National MortgagePairCorr
  0.76AXP American Express Fiscal Year End 24th of January 2025 PairCorr
  0.7TRV The Travelers Companies Fiscal Year End 17th of January 2025 PairCorr
  0.45CIB Bancolombia SA ADRPairCorr
  0.43AVAL Grupo AvalPairCorr
  0.43ITCL Banco Ita ChilePairCorr

Eli Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CEOJacob Naarden
Thematic Ideas
(View all Themes)
Old Names[Eli Lilly and Company, Eli Lilly and Company]
Business ConcentrationPharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, NYSE 100 Index, SP 500 Index, ARCA Institutional, ARCA Pharmaceutical, SP 100, SP 100 Index, Compulsion, ESG Investing, Healthcare, Health Care, Pharmaceuticals, Drug Manufacturers—General, Healthcare (View all Sectors)
Excise Tax ActivitiesAnimal Testing
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.70.5331
Significantly Up
Slightly volatile
Gross Profit Margin0.620.7925
Significantly Down
Pretty Stable
Total Current Liabilities28.7 B27.3 B
Sufficiently Up
Slightly volatile
Non Current Liabilities Total27.1 B25.8 B
Sufficiently Up
Slightly volatile
Total Assets67.2 B64 B
Sufficiently Up
Slightly volatile
Total Current Assets27 B25.7 B
Sufficiently Up
Slightly volatile
Total Cash From Operating Activities4.3 B4.2 B
Fairly Up
Slightly volatile
Debt Levels
Eli Lilly can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Eli Lilly's financial leverage. It provides some insight into what part of Eli Lilly's total assets is financed by creditors.
Liquidity
Eli Lilly and has 25.23 B in debt with debt to equity (D/E) ratio of 1.58, which is OK given its current industry classification. Eli Lilly has a current ratio of 1.11, demonstrating that it may not be capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Eli to invest in growth at high rates of return.

Capital Expenditures

7.76 Billion
Eli Lilly and (LLY) is traded on New York Stock Exchange in USA. It is located in Lilly Corporate Center, Indianapolis, IN, United States, 46285 and employs 43,000 people. Eli Lilly is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with a total capitalization of 715.27 B. Eli Lilly runs under Pharmaceuticals sector within Health Care industry. The entity has 899.32 M outstanding shares of which 6.54 M shares are now shorted by investors with about 1.54 days to cover. Eli Lilly and has about 2.07 B in cash with 4.24 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.97.
Check Eli Lilly Probability Of Bankruptcy
Ownership Allocation
Eli Lilly holds a total of 899.32 Million outstanding shares. The majority of Eli Lilly and outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Eli Lilly to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Eli Lilly. Please pay attention to any change in the institutional holdings of Eli Lilly and as this could imply that something significant has changed or is about to change at the company. Please note that on November 7, 2024, Senator Sheldon Whitehouse of US Senate acquired $15k to $50k worth of Eli Lilly's common stock.
Check Eli Ownership Details

Eli Stock Institutional Holders

InstituionRecorded OnShares
Geode Capital Management, Llc2024-09-30
17.1 M
State Farm Mutual Automobile Ins Co2024-09-30
12.6 M
International Assets Investment Management, Llc2024-09-30
12.5 M
Norges Bank2024-06-30
11 M
Bank Of America Corp2024-06-30
10.8 M
Wellington Management Company Llp2024-06-30
10.8 M
Capital Research Global Investors2024-09-30
9.3 M
Northern Trust Corp2024-09-30
8.2 M
Legal & General Group Plc2024-06-30
7.1 M
Lilly Endowment Inc2024-09-30
96.9 M
Vanguard Group Inc2024-09-30
73.8 M
View Eli Lilly Diagnostics

Eli Lilly Historical Income Statement

At this time, Eli Lilly's Interest Expense is fairly stable compared to the past year. Total Revenue is likely to rise to about 35.8 B in 2024, whereas Depreciation And Amortization is likely to drop slightly above 941.5 M in 2024. View More Fundamentals

Eli Stock Against Markets

Eli Lilly Corporate Directors

Kathi SeifertIndependent DirectorProfile
Jamere JacksonIndependent DirectorProfile
Juan LucianoLead Independent DirectorProfile
Gabrielle SulzbergerIndependent DirectorProfile

Additional Tools for Eli Stock Analysis

When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.